You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ)子公司獲得日本專利證書涉羥基嘌呤類化合物及其應用
格隆匯 08-16 19:43

格隆匯8月16日丨眾生藥業(002317.SZ)公佈,近日,公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)收到日本特許廳(Japan Patent Office)頒發的專利證書。

專利名稱為ヒドロキシプリン化合物及びその応用(羥基嘌呤類化合物及其應用);專利申請日為2015年09月22日;專利權期限為自申請日起二十年。

該專利是公司控股子公司眾生睿創用於治療非酒精性脂肪性肝炎(NASH)的創新藥物ZSP1601項目的化合物專利,屬於該項目的核心專利。ZSP1601片是國內第一個獲得臨牀試驗批件並具有全新作用機制用於治療NASH的創新藥物,也是首個完成健康人藥代及安全性臨牀試驗的用於治療NASH的國內創新藥項目,並且是首個進入評價NASH患者早期藥效學臨牀試驗的國內創新藥項目,目前已獲得組長單位吉林大學第一醫院Ib/IIa期臨牀試驗倫理批件。

ZSP1601項目化合物核心專利目前已獲得包括南非、美國、新西蘭、俄羅斯、加拿大、澳大利亞、中國、日本等國的專利授權,ZSP1601項目的全球知識產權保護體系逐漸完善。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account